

Special Issue

Advances in Personalized Treatment of Breast Cancer

Message from the Guest Editor

Breast cancer is commonly considered an international health priority, it is the most common tumour in women in the world, and epidemiological data show a progressive increase in its incidence. The evolution of evidence-based guidelines in important disciplines such as surgery, radiotherapy, and medical oncology is leading to a steady improvement in survival rates. The management of breast cancer has progressively evolved towards less aggressive approaches with the adoption of new therapeutic strategies based on integrated and precision oncology. Treatments are personalized for each patient and based on individual peculiarities (age, associated pathologies, presence of genetic mutations) and on the characteristics of the disease (staging, biological, molecular, and genomic profiles). This Special Issue will highlight the recent advances in personalized breast cancer treatment, their potential benefits, and the many open questions that have yet to be properly defined and answered. We invite the following types of manuscripts: original research articles; meta-analyses; systematic reviews; review articles; method articles; perspective articles; and technology reports.

Guest Editor

Dr. Gianluca Franceschini

Breast Unit, Dipartimento Scienze della Salute della Donna e del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica, Rome, Italy

Deadline for manuscript submissions

10 July 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/177907

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/jpm)

[jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).